GAM Holding AG Sells 57,182 Shares of Haleon plc (NYSE:HLN)

GAM Holding AG lessened its stake in shares of Haleon plc (NYSE:HLN) by 6.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 792,102 shares of the company’s stock after selling 57,182 shares during the period. GAM Holding AG’s holdings in Haleon were worth $7,557,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sierra Ocean LLC acquired a new stake in shares of Haleon during the 4th quarter worth $26,000. Fortitude Family Office LLC acquired a new stake in Haleon during the third quarter worth about $28,000. Versant Capital Management Inc increased its holdings in Haleon by 2,029.1% in the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock valued at $34,000 after buying an additional 3,348 shares during the period. Geneos Wealth Management Inc. acquired a new position in shares of Haleon in the 4th quarter valued at approximately $35,000. Finally, Toronto Dominion Bank lifted its holdings in shares of Haleon by 3,470.0% during the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after acquiring an additional 3,470 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Price Performance

HLN stock opened at $9.71 on Tuesday. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The stock has a market cap of $43.94 billion, a price-to-earnings ratio of 28.54, a P/E/G ratio of 2.70 and a beta of 0.28. The company has a 50 day simple moving average of $9.54 and a 200 day simple moving average of $9.81.

Analyst Upgrades and Downgrades

Several research analysts have commented on HLN shares. Morgan Stanley downgraded shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.